Wedbush upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a neutral rating to an outperform rating in a research report sent to investors on Friday morning, MarketBeat Ratings reports. The firm currently has $19.00 target price on the stock.

Several other research firms have also issued reports on KPTI. HC Wainwright reiterated a buy rating and issued a $30.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, August 29th. BidaskClub upgraded shares of Karyopharm Therapeutics from a sell rating to a hold rating in a research report on Thursday. ValuEngine lowered shares of Karyopharm Therapeutics from a strong-buy rating to a buy rating in a research report on Thursday, October 11th. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a hold rating to a buy rating and set a $21.00 price target for the company in a research report on Wednesday, July 25th. Finally, Robert W. Baird restated a buy rating and set a $25.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 8th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $22.90.

Shares of NASDAQ KPTI traded up $0.05 during trading on Friday, hitting $11.60. The stock had a trading volume of 786,589 shares, compared to its average volume of 933,786. Karyopharm Therapeutics has a 12 month low of $9.00 and a 12 month high of $21.71. The firm has a market cap of $721.92 million, a price-to-earnings ratio of -4.13 and a beta of 3.93.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, November 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.88) by $0.09. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $1.21 million. Equities analysts forecast that Karyopharm Therapeutics will post -3.18 EPS for the current fiscal year.

In related news, CEO Michael Kauffman sold 10,000 shares of the stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $17.46, for a total transaction of $174,600.00. Following the completion of the transaction, the chief executive officer now owns 522,143 shares in the company, valued at $9,116,616.78. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Sharon Shacham sold 12,500 shares of the stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $11.65, for a total transaction of $145,625.00. Following the transaction, the insider now owns 726,010 shares of the company’s stock, valued at approximately $8,458,016.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 735,788 shares of company stock valued at $14,720,105. 13.26% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Voya Investment Management LLC lifted its holdings in Karyopharm Therapeutics by 24.3% during the second quarter. Voya Investment Management LLC now owns 18,661 shares of the company’s stock valued at $317,000 after purchasing an additional 3,653 shares during the last quarter. Metropolitan Life Insurance Co. NY lifted its holdings in Karyopharm Therapeutics by 38.9% during the second quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock valued at $277,000 after purchasing an additional 4,556 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Karyopharm Therapeutics by 2.1% during the third quarter. Bank of New York Mellon Corp now owns 218,594 shares of the company’s stock valued at $3,723,000 after purchasing an additional 4,576 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Karyopharm Therapeutics by 16.3% during the first quarter. Wells Fargo & Company MN now owns 36,036 shares of the company’s stock valued at $483,000 after purchasing an additional 5,062 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its holdings in Karyopharm Therapeutics by 20.9% during the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,090 shares of the company’s stock valued at $683,000 after purchasing an additional 6,920 shares during the last quarter. Institutional investors own 71.83% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

See Also: What does earnings per share mean?

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.